Home・Lista de Ações・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Abrir

SetorSaúde

468.05 -4.68

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

459

Máximo

494.4

Indicadores-chave
By Trading Economics
Rendimento	-36M -94M
Vendas	-9.7M 311M
EPS	-1.38
Margem de lucro	-30.318
Funcionários	915
EBITDA	-36M -86M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+39.91% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	751M 13B
Abertura anterior	472.73
Fecho anterior	468.05

Sentimento de Notícias

By Acuity

64%

36%

292 / 340 Ranking em Healthcare

Madrigal Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de jul. de 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29 de jul. de 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28 de jul. de 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27 de jul. de 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 de jul. de 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Comparação entre Pares

Variação de preço

Madrigal Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

39.91% parte superior

Previsão para 12 meses

Média 689.93 USD 39.91%

Máximo 964 USD

Mínimo 543 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

292 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.